Drug Repurposing Market: Future Demand and Top Key Players Analysis | 2029

 This market research is a valuable tool for leaders seeking to align their strategies with the realities and opportunities in the drug repurposing industry.

 

 How Much Is The Drug Repurposing Market Worth?
 The drug repurposing market size has grown strongly in recent years. It will grow from $34.12 billion in 2024 to $37.38 billion in 2025 at a compound annual growth rate (CAGR) of 9.5%. The growth in the historic period can be attributed to the rising cost of novel drug development, increasing drug failures in clinical trials, a rise in demand for faster drug approval, increasing availability of off-patent drugs, and rising government and academic research funding.
 
 The drug repurposing market size is expected to see strong growth in the next few years. It will grow to $53.42 billion in 2029 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to increasing demand for cost-effective therapies, growing investments from pharmaceutical companies, increasing collaborations among biotech firms, and expanding applications in oncology and neurology. Major trends in the forecast period include advancements in computational drug discovery tools, advanced use of AI and ML in drug repurposing, innovation in predictive modeling for drug efficacy, integration of big data analytics in drug screening, and advancements in biomarker identification.
 
 Get your free sample today:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=25758&type=smp
 
 What Are The Current Leading Growth Drivers For Drug Repurposing Market?
 The growing prevalence of neurodegenerative diseases is expected to propel the growth of the drug repurposing market going forward. Neurodegenerative diseases refer to a group of disorders characterized by the progressive loss of structure or function of neurons, including their death. The rise in neurodegenerative diseases such as alzheimer’s dementia is due to increased life expectancy, as aging is the primary risk factor that contributes to the gradual decline of neuronal function over time. Drug repurposing helps neurodegenerative diseases by identifying existing drugs with known safety profiles that can be redirected to target disease pathways, accelerating the development of effective treatments. For instance, in March 2023, according to the Alzheimer’s Association, a US-based nonprofit voluntary health organization, in 2023, about 6.7 million Americans aged 65 and older are living with Alzheimer’s dementia, with projections indicating an increase to 13.8 million by 2060. Therefore, the growing prevalence of neurodegenerative diseases is driving the growth of the drug repurposing market.
 
 Which Segment Accounted For The Largest Drug Repurposing Market Share?
 The drug repurposing market covered in this report is segmented — 
 
 1) By Type: Disease-Centric, Target-Centric, Drug-Centric
 2) By Drug Molecules: Biologics, Small Molecule
 3) By Therapeutic Area: Oncology, Neurology, Infectious Diseases, Cardiovascular Diseases, Autoimmune Disorders
 4) By Route Of Administration: Oral, Intravenous, Topical, Inhalation, Intramuscular
 5) By End-User: Pharmaceutical Companies, Research And Academic Institutes, Contract Research Organizations
 
 Subsegments:
 1) By Disease-Centric: Phenotypic Screening, Epidemiological Analysis, Clinical Observation-Based Repurposing
 2) By Target-Centric: Protein Target Modulation, Pathway Modulation, Biomarker-Based Targeting
 3) By Drug-Centric: Off-Target Activity Identification, Structure-Based Drug Repositioning, Adverse Effect-Based Repurposing
 
 Drug Repurposing Market Emerging Trends And Opportunities
 Major companies operating in the drug repurposing market are focusing on developing advanced technologies such as artificial intelligence (AI)-powered drug-protein interaction modeling to accelerate the identification of new therapeutic uses for existing drugs. Artificial intelligence (AI)-powered drug-protein interaction modeling leverages artificial intelligence and machine learning to predict how drugs interact with proteins across the human proteome, using expansive datasets to enhance accuracy and confidence. For instance, in July 2025, Cosmos Health Inc., a US-based healthcare company, unveiled Cloudscreen 2.0, an advanced AI platform for drug repurposing. It is a next-generation system designed to process datasets over 100 times larger than before, enabling comprehensive analysis of drug-protein interactions. By incorporating mutagenesis data and tools for analyzing disordered proteins, the platform targets diseases such as cancer, obesity, and diabetes. Additionally, graphics processing unit (GPU)-based cloud computing empowers scalable processing, making the platform a critical innovation in accelerating research and development pipelines for drug repurposing across multiple therapeutic areas.
 
 Which Are The Top Companies To Hold The Market Share In Drug Repurposing Market?
 Major companies operating in the drug repurposing market are F. Hoffmann-La Roche Ltd , International Business Machines Corporation (IBM), Bayer AG, Takeda Pharmaceutical Company Limited, Amgen Inc., Teva Pharmaceutical Industries Limited, Astellas Pharma Inc., UCB S.A., Eisai Co Ltd., Celltrion Inc., Alnylam Pharmaceuticals Inc., Evotec SE, BenevolentAI Limited, Insilico Medicine Inc., Cosmos Health Inc., Recursion Pharmaceuticals Inc., Pharnext S.A., Healx Ltd., Algernon Pharmaceuticals Inc., BioXcel Therapeutics Inc. 
 
 View the full drug repurposing market report here:
 https://www.thebusinessresearchcompany.com/report/drug-repurposing-global-market-report
 
 Which Region Is Projected To Account For The Largest Share Of The Drug Repurposing Market?
 North America was the largest region in the drug repurposing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug repurposing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
 
 Contact Us:
 
 The Business Research Company 
 
 https://thebusinessresearchcompany.com/ 
 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 
 Email: info@tbrc.info 
 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company